Analysis – Goldea Capital

Sanuwave Announces Record Revenues and Financial Results for Q4 and Full Year 2025

Written by Customer Service on March 26, 2026. Posted in Earnings Releases And Operating Results.

Q4 2025 revenues were $13.4 million, up 29.7% from Q4 2024. This was an all-time quarterly record for the Company. Full year 2025 revenues were $44.1 million up 35.0% from full year 2024 revenues. This was an all-time annual record for the Company. Q4 2025 gross margin was 74.7%, versus 77.9% in Q4 2024 and 77.6% in Q3 2025. Full year 2025 gross margin was 77.1% versus 75.2% in 2024. GAAP Operating Income was $2.0 million for Q4 2025 and $4.9 million for full year 2025. Company provides guidance for revenues of $9.6-10.3 million (an increase of 3-10%) for Q1 2026 as compared to Q1 2025 and initiates full year 2026 revenue guidance of 16-25% growth vs 2025 ($51.0-55.0 million). EDEN PRAIRIE, Minn., March 26, 2026 (GLOBE NEWSWIRE) — Sanuwave Health, Inc. (the “Company” or “Sanuwave”) (NASDAQ: SNWV), a leading...

DBV Technologies Announces Filing of 2025 Annual Report on Form 10-K and Universal Registration Document

Written by Customer Service on March 26, 2026. Posted in Public Companies.

Châtillon, France, March 26, 2026 DBV Technologies Announces Filing of 2025 Annual Report on Form 10-K and Universal Registration Document DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a late-stage biopharmaceutical company (the “Company”), today announced the filing, for the year ended December 31, 2025, of its Annual Report on Form 10-K with the U.S. Securities and Exchange Commission (“SEC”) and its Universal Registration Document (“ 2025 URD”) with the French market authority, “Autorité des Marchés Financiers” (“AMF”). In compliance with French law, the following information are included in the 2025 URD :The 2025 annual financial report; The Board of Directors’ corporate governance report (“rapport sur le gouvernement d’entreprise”) required under Article L. 225-37 of the French Commercial...

Firan Technology Group Corporation (“FTG”) Announces First Quarter 2026 Earnings Release and Conference Call Dates

Written by Customer Service on March 26, 2026. Posted in Public Companies.

TORONTO, March 26, 2026 (GLOBE NEWSWIRE) — Firan Technology Group Corporation (TSX: FTG) (OTCQX: FTGFF) (“FTG”) will release the first quarter 2026 financial results after the market closes on Wednesday, April 8, 2026. The Corporation will host a live conference call on Thursday, April 9, 2026, at 8:30am (Eastern Time) to discuss the first quarter of 2026 financial results. Anyone wishing to participate in the call should dial 289-514-5100 or 1-800-717-1738, Conference ID 33073, and identify that you are calling to participate in the FTG conference call. The Chairperson is Mr. Brad Bourne. A replay of the call will be available until May 11, 2026, and will be available on the FTG website at www.ftgcorp.com. The number to call for a rebroadcast is 289-819-1325 or 1-888-660-6264, Playback Passcode 33073. ABOUT FIRAN TECHNOLOGY GROUP...

Lassonde Industries Inc. announces its Q4 and fiscal 2025 results

Written by Customer Service on March 26, 2026. Posted in Earnings Releases And Operating Results.

ROUGEMONT, Quebec, March 26, 2026 (GLOBE NEWSWIRE) — Lassonde Industries Inc. (TSX: LAS.A) (“Lassonde” or the “Corporation”) today announced its financial results for its fourth quarter and year ended December 31, 2025. Financial Highlights: Fourth quarters ended Years endedDec. 31,2025 Dec. 31,2024 ∆ Dec. 31,2025 Dec. 31,2024 ∆(in millions of dollars, unless otherwise indicated) $ $ $ $ $ $Sales 768.1 738.1 30.0 2,934.0 2,600.9 333.1 Gross profit 225.0 192.9 32.1 801.5 698.1 103.4 Operating profit 71.1 43.0 28.1 226.1 174.7 51.4 Profit 54.2 27.8 26.4 149.4 113.4 36.0 Attributable to: Corporation’s shareholders 54.0 27.1 26.9 149.7 114.1 35.6 Non-controlling interests 0.2 0.7 (0.5 ) (0.3 ) (0.7 ) 0.4 EPS (in $) 7.92 3.97 3.95 21.94 16.73 5.21 Weighted...

LeonaBio Reports Full Year 2025 Financial Results and Provides Business Update

Written by Customer Service on March 26, 2026. Posted in Earnings Releases And Operating Results.

Acquired License to Phase 3 Lasofoxifene Development Program of Novel Selective Estrogen Receptor Modulator (SERM), a Potential Multi-Billion Dollar Opportunity as Treatment Option for Breast Cancer Patients with ESR1-Mutations Received Gross Proceeds of $90 Million in Private Placement Financing of Common Stock and Warrants with Cash-Exercisable Warrants Potentially Providing up to an Additional $146 Million to Support Development of Lasofoxifene Through Key Clinical and Regulatory Milestones Expect to Complete Enrollment of Phase 3 Clinical Trial of Lasofoxifene in ER-positive (ER+), HER2-negative, ESR1-mutated Metastatic Breast Cancer in 4Q 2026 with Topline Data Anticipated in 2H 2027 On-track to Initiate Phase 2 Proof-of-Concept Study of ATH-1105 in ALS patients in 2H 2026 BOTHELL, Wash., March 26, 2026 (GLOBE NEWSWIRE) — LeonaBio,...

KULR Technology Group Sets Fourth Quarter and Full Year 2025 Earnings Call for Tuesday, March 31, 2026 at 4:30 p.m. ET

Written by Customer Service on March 26, 2026. Posted in Public Companies.

HOUSTON, March 26, 2026 (GLOBE NEWSWIRE) — KULR Technology Group, Inc. (NYSE American: KULR) (the “Company” or “KULR”), the advanced battery intelligence solution for autonomous platforms, digital infrastructure, e-mobility, and spaceflight applications, will hold a conference call on Tuesday, March 31st at 4:30 p.m. Eastern time (1:30 p.m. Pacific time) to discuss its financial results for the fourth quarter and full year ended December 31, 2025. The financial results will be issued in a press release prior to the call. KULR management will host the conference call, followed by a question-and-answer period. Interested parties can submit relevant questions prior to the call to Stuart Smith via email: ir@kulr.ai by 11:00 a.m. ET on Sunday, March 29th, 2026. Mr. Smith will compile a list of questions and submit...

Thor Equities Acquires Prime Mixed-Use Asset at 1165 Broadway in NYC’s NoMad District

Written by Customer Service on March 26, 2026. Posted in Mergers And Acquisitions.

Firm expands portfolio with $56 Million purchase of 58,000-SF office and retail property New York, NY, March 26, 2026 (GLOBE NEWSWIRE) — Thor Equities, a global leader in real estate development, leasing, and asset management, today announced the acquisition of 1165 Broadway, a 58,000-square-foot, mixed-use office and retail property for $56 Million. Located in the heart of Manhattan’s NoMad District, the asset is 100% occupied by a strong roster of creative retail and office tenants. Situated between 27th and 28th Streets, 1165 Broadway is a historic building designed by Charles Mellon in 1867, originally home to the Coleman House Hotel. The fully leased property offers exceptional visibility, transit access, and close proximity to Madison Square Park. Current tenants include global luxury brand Christian Louboutin, premium skincare...

XORTX Announces Change of Effective Date of Share Consolidation

Written by Customer Service on March 26, 2026. Posted in Public Companies.

CALGARY, Alberta, March 26, 2026 (GLOBE NEWSWIRE) — XORTX Therapeutics Inc. (“XORTX” or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, announces that, further to its news release of March 25, 2026, the Company has delayed the implementation of its share consolidation on the basis of one (1) new common share for every five (5) old common shares (the “Consolidation”) from March 27, 2026 to April 6, 2026, and remains subject to the receipt of all required approvals of the TSX Venture Exchange and Nasdaq Stock Exchange. About XORTX Therapeutics Inc. XORTX is a pharmaceutical company with three clinically advanced products in development: 1) our lead program XRx-026 program for the treatment...

Proposed Merger Approved by Shareholders of CVB Financial Corp. and Shareholders of Heritage Commerce Corp.

Written by Customer Service on March 26, 2026. Posted in Mergers And Acquisitions.

ONTARIO, Calif. and SAN JOSE, Calif., March 26, 2026 (GLOBE NEWSWIRE) — CVB Financial Corp. (NASDAQ: CVBF), the holding company for Citizens Business Bank, and Heritage Commerce Corp (NASDAQ: HTBK), the holding company for Heritage Bank of Commerce, today jointly announced that each company’s respective shareholders have voted to approve the proposed merger of Heritage Commerce Corp with and into CVB Financial Corp. Subject to the receipt of regulatory approvals and satisfaction of all remaining closing conditions set forth in the merger agreement, the parties anticipate consummating the merger in the second quarter of 2026. About CVB Financial Corp. CVB Financial Corp. (“CVBF”) is the publicly traded holding company for Citizens Business Bank, National Association. CVBF is one of the 10 largest bank holding companies headquartered...

Inspira Technologies Reports Full Year 2025 Financial Results and Provides Business Updates

Written by Customer Service on March 26, 2026. Posted in Earnings Releases And Operating Results.

Company Demonstrates Clinical Validation and Early Commercial Traction Toward 2026 Revenue Scale RA’ANANA, Israel, March 26, 2026 (GLOBE NEWSWIRE) — Inspira™ Technologies OXY B.H.N. Ltd. (Nasdaq: IINN) (“Inspira” or the “Company”), a pioneer in innovative life-support and diagnostic technologies, today announced its financial results for the full year ended December 31, 2025, and provided a corporate update. Dagi Ben-Noon, Chief Executive Officer of Inspira, commented: “2025 marked a pivotal year for Inspira as we advanced from clinical validation into early commercial execution. Throughout 2025 and since year-end, we saw meaningful progress across multiple commercialization pathways for the INSPIRA™ ART100 system, including active clinical use at leading medical centers, advancement of...

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals